Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:31:07.850Z.
Consensus retrieved: 2026-10-06T10:44:23.891Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:31:07.850Z.
Quote observation: 2026-10-06T18:29:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c853c120bd8ccf37c7f587defdd96232933b3c15f4f3e57031eea60a2967291
Forward PE Ratio (N/A) = Dated Quote Price ($0.84) / Consensus Forward EPS ($-0.78)
FORWARD PE RATIO
N/A
Dare Bioscience, Inc.
Market Cap
$12.54M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Dare Bioscience, Inc. (DARE) | $12.54M | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.56M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.46M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.66M | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.40M | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.35M | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.19M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.22M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.40M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.84, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.78 | $-1.04 – $-0.52 | 2 | n/m |
| 2027-12-31 | $-0.41 | $-0.61 – $-0.25 | 1 | n/m |
| 2028-12-31 | $0.12 | $0.06 – $0.18 | 2 | 7.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
